KISUNLA

Boxed Warning — Kisunla: Kisunla can cause amyloid-related imaging abnormalities (ARIA), including ARIA-E (brain edema or sulcal effusions) and ARIA-H (microhemorrhage and superficial siderosis). ARIA is usually asymptomatic, but serious and life-threatening events, including seizures, can occur. Risk is higher in patients who are ApoE ε4 homozygotes and those with pre-existing microhemorrhages or superficial siderosis. Regular MRI monitoring is required throughout treatment.

Kisunla Warnings and Precautions

• ARIA monitoring: MRI scans are required at baseline and before specified infusions to detect ARIA before it becomes symptomatic.
• Infusion-related reactions: Can occur during or shortly after infusion, including flu-like symptoms, nausea, and changes in blood pressure.
• ApoE ε4 genotype testing: Testing is recommended before starting treatment to help assess ARIA risk.
• Not for all forms of dementia: Kisunla is intended only for patients with confirmed amyloid pathology and early symptomatic Alzheimer's disease, not other causes of cognitive decline.

How to Access Kisunla in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Kisunla to India?

Kisunla (donanemab-azbt) injection may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:

• A valid prescription from a qualified neurologist
• The patient's diagnostic reports, including confirmed amyloid pathology and MRI baseline scan
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.

Is Kisunla available in India?

Kisunla (donanemab-azbt injection) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Kisunla is not commercially marketed in India.

However, patients in India can legally access Kisunla through the Named Patient Program (NPP) — an import provision that allows patients to receive medicines approved in other countries but not yet marketed in India, under a doctor's prescription and proper regulatory documentation.

Kisunla received US FDA approval in July 2024 for early symptomatic Alzheimer's disease with confirmed amyloid pathology, ensuring full transparency throughout the process.

Kisunla can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others.

For patients with early symptomatic Alzheimer's disease, NPP also facilitates access to Leqembi, another amyloid-targeting therapy, based on the treating neurologist's assessment.

Sourcing & Delivery of Kisunla

Kisunla is sourced directly from authorized channels in the country of origin and shipped to India under GDP-compliant, cold-chain logistics to preserve product integrity from dispatch to delivery.

• Cold-chain shipping maintained at 2°C to 8°C throughout transit
• Real-time shipment tracking and delivery updates
• Delivery coordinated directly with the patient, family, or treating hospital

Availability of Kisunla Across Major Cities in India

Named Patient Program supports access to Kisunla for patients with early symptomatic Alzheimer's disease across major cities in India, coordinating documentation, sourcing, and delivery with treating neurologists.

Mumbai

Patients in Mumbai can access Kisunla through NPP with support from treating neurologists at the city's leading memory and cognitive care centers.

Delhi

In Delhi, NPP coordinates with hospitals and specialty neurology clinics to facilitate timely access to Kisunla.

Bangalore

Bangalore's neurology and imaging centers work with NPP to support patients requiring Kisunla and its required MRI monitoring.

Chennai

Patients in Chennai can access Kisunla through NPP, with coordination between treating doctors and the program's regulatory and logistics team.

Hyderabad

Hyderabad's neurology and diagnostic imaging centers support diagnosis and access coordination for Kisunla through NPP.

Kolkata

NPP facilitates access to Kisunla for patients in Kolkata under the guidance of treating neurologists.

Pune

Patients in Pune can access Kisunla through NPP with prescription-based coordination and cold-chain delivery support.

Ahmedabad

NPP supports access to Kisunla for patients in Ahmedabad, working directly with treating specialists.

Kochi

Patients in Kochi and across Kerala can access Kisunla through NPP's regulated import pathway.

Chandigarh

NPP coordinates access to Kisunla for patients in Chandigarh and the surrounding region.

Jaipur

Patients in Jaipur can access Kisunla through NPP with support from treating neurologists.

Lucknow

NPP facilitates access to Kisunla for patients in Lucknow and across Uttar Pradesh.

Bhubaneswar

Patients in Bhubaneswar can access Kisunla through NPP's coordinated import and delivery process.

Guwahati

NPP supports access to Kisunla for patients in Guwahati and across the Northeast region.

NPP also supports access for patients in other Indian cities not listed above — contact the team to check availability and timelines for your location.